BioNTech (BNTX) investor relations material

Opening remarks and agenda

• The AGM was opened virtually, with shareholders able to participate electronically via the investor portal or view the meeting in multiple languages through the website.

• Formalities included confirmation of proper convening, technical arrangements, and legal compliance; the agenda and management's proposed resolutions were published in advance.

• The list of participants was compiled and attendance figures announced before voting.

Board and executive committee updates

• No changes occurred in the Supervisory Board during 2025; Nicola Blackwood participated virtually due to a prior commitment.

• Jens Holstein retired as CFO on June 30, 2025, succeeded by Ramón Zapata from July 1, 2025; Ryan Richardson stepped down as Chief Strategy Officer.

• Sierk Pötting’s contract as COO was extended through December 31, 2027.

• Kylie Jimenez was appointed Chief Human Resources Officer effective March 1, 2026.

Financial performance review

• 2025 revenues reached EUR 2.9 billion, slightly up from the prior year, with COVID-19 vaccine revenue declines offset by EUR 613 million from the BMS collaboration.

• R&D expenses were EUR 2.1 billion, slightly down year-over-year, reflecting portfolio management and cost sharing with BMS.

• Q1 2026 revenues were EUR 118 million, with R&D expenses at EUR 557 million, reflecting increased investment in oncology and ADC programs.

• Cash and securities stood at EUR 16.8 billion at the end of Q1 2026, supporting ongoing investments.

• 2026 revenue guidance is EUR 2–2.3 billion, with R&D expenses expected at EUR 2.2–2.5 billion.